CE: Chronic CAD and PAD: Reducing Major Adverse Cardiovascular Events With Dual Pathway Inhibition Antithrombotic Therapy

Pharmacy Times, October 2020, Volume 88, Issue 10

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

EDUCATIONAL OBJECTIVES

At the completion of this activity, the participant will be able to:

  • Examine the burden of coronary artery disease (CAD) and peripheral artery disease (PAD) along with suboptimal treatment in secondary prevention
  • Compare the guidelines for secondary prevention in CAD and PAD and the most recent clinical data on dual pathway therapy
  • Identify the pharmacist’s role for evaluating benefit versus risk in appropriate patients for CAD and PAD as well as the importance of medication therapy management

FACULTY

Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP

Professor of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center; Omaha, Nebraska

TARGET AUDIENCE: Health-system and retail pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: October 15, 2020

EXPIRATION DATE: November 15, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.